| Simulated brain tumor growth dynamics using a three-dimensional cellular automaton AR Kansal, S Torquato, GR Harsh, EA Chiocca, TS Deisboeck Journal of theoretical biology 203 (4), 367-382, 2000 | 596 | 2000 |
| Pattern of self‐organization in tumour systems: complex growth dynamics in a novel brain tumour spheroid model TS Deisboeck, ME Berens, AR Kansal, S Torquato, ... Cell Proliferation 34 (2), 115-134, 2001 | 268 | 2001 |
| Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective SV Sorensen, AR Kansal, S Connolly, S Peng, J Linnehan, ... Thrombosis and haemostasis 105 (05), 908-919, 2011 | 264 | 2011 |
| Diversity of order and densities in jammed hard-particle packings AR Kansal, S Torquato, FH Stillinger Physical Review E 66 (4), 041109, 2002 | 243 | 2002 |
| Computer generation of dense polydisperse sphere packings AR Kansal, S Torquato, FH Stillinger The Journal of chemical physics 117 (18), 8212-8218, 2002 | 215 | 2002 |
| Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation AR Kansal, SV Sorensen, R Gani, P Robinson, F Pan, JM Plumb, ... Heart 98 (7), 573-578, 2012 | 144 | 2012 |
| Cellular automaton of idealized brain tumor growth dynamics AR Kansal, S Torquato, GR Harsh Iv, EA Chiocca, TS Deisboeck Biosystems 55 (1-3), 119-127, 2000 | 141 | 2000 |
| Emergence of a subpopulation in a computational model of tumor growth AR Kansal, S Torquato, EA Chiocca, TS Deisboeck Journal of Theoretical Biology 207 (3), 431-441, 2000 | 130 | 2000 |
| Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation F Skjøth, TB Larsen, LH Rasmussen, GYH Lip Thrombosis and haemostasis 112 (05), 981-988, 2014 | 129 | 2014 |
| Nonequilibrium hard-disk packings with controlled orientational order AR Kansal, TM Truskett, S Torquato The Journal of Chemical Physics 113 (12), 4844-4851, 2000 | 81 | 2000 |
| Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada AR Kansal, M Sharma, C Bradley-Kennedy, A Clemens, BU Monz, ... Thrombosis and haemostasis 108 (10), 672-682, 2012 | 78 | 2012 |
| Defining virtual patient populations C Friedrich, A Kansal, D Klinke, S Michelson, T Paterson, D Polidori, ... US Patent App. 11/346,990, 2007 | 71 | 2007 |
| Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK A Hackshaw, SS Cohen, H Reichert, AR Kansal, KC Chung, JJ Ofman British Journal of Cancer 125 (10), 1432-1442, 2021 | 69 | 2021 |
| Modeling approaches to type 2 diabetes AR Kansal Diabetes technology & therapeutics 6 (1), 39-47, 2004 | 58 | 2004 |
| A cellular automaton model of brain tumor treatment and resistance JE Schmitz, AR Kansal, S Torquato Journal of Theoretical Medicine 4 (4), 223-239, 2002 | 58 | 2002 |
| Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting Y Zheng, SV Sorensen, AK Gonschior, H Noack, J Heinrich-Nols, ... Clinical therapeutics 36 (12), 2015-2028. e2, 2014 | 57 | 2014 |
| Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation AR Kansal, Y Zheng, T Pokora, SV Sorensen Best Practice & Research Clinical Haematology 26 (2), 225-237, 2013 | 45 | 2013 |
| Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial A Kansal, OS Reifsnider, I Proskorovsky, Y Zheng, E Pfarr, JT George, ... Diabetic Medicine 36 (11), 1494-1502, 2019 | 44 | 2019 |
| Cost‐effectiveness of ivabradine for heart failure in the United States AR Kansal, MR Cowie, A Kielhorn, S Krotneva, A Tafazzoli, Y Zheng, ... Journal of the American Heart Association 5 (5), e003221, 2016 | 38 | 2016 |
| Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design AR Kansal, J Trimmer IEE Proceedings-Systems Biology 152 (4), 214-220, 2005 | 35 | 2005 |
David PolidoriJohnson & Johnson Innovative MedicineVerified email at its.jnj.com
